Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Teva Pharmaceutical Industries Days Payable?
Teva Pharmaceutical IndustriesBSP:T1EV34 -2.94%10 Days Payable is 118.92 as of Mar. 2026, which is 60% above its 10-year median of 74.19. GuruFocus rates BSP:T1EV34 with a GF Score™ of 10/100 and a GF Value™ of R$52.47 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 927 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks better than 60.84% on this metric.
The historical rank and industry rank for Teva Pharmaceutical Industries's Days Payable or its related term are showing as below:
BSP:T1EV34'
s Days Payable Range Over the Past 10 Years
Min: 68.63 Med: 74.19 Max: 107.74
Current: 107.74
During the past 13 years, Teva Pharmaceutical Industries's highest Days Payable was 107.74. The lowest was 68.63. And the median was 74.19.
BSP:T1EV34's Days Payable is ranked better than 60.84% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BSP:T1EV34: 107.74
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:T1EV34 vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Days Payable distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's Days Payable falls into.
Teva Pharmaceutical Industries Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries (BSP:T1EV34) has a Days Payable of 118.92 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Teva Pharmaceutical Industries and its competitors. This is 60% above median its historical median of 74.19. Over the past decade, Teva Pharmaceutical Industries' Days Payable has ranged from 68.63 to 107.74. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #363 out of 927 companies in the Drug Manufacturers industry, placing it in the top 39.2%.
Is Teva Pharmaceutical Industries' Days Payable too high?
Teva Pharmaceutical Industries' current Days Payable of 118.92 is 60% above median its 10-year median of 74.19. Over the past 10 years, this metric has ranged from a low of 68.63 to a high of 107.74. The Drug Manufacturers industry median Days Payable is 90.38. Teva Pharmaceutical Industries' value of 118.92 is 31.6% above this industry median. Based on the distribution chart, Teva Pharmaceutical Industries ranks #363 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Teva Pharmaceutical Industries has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #363 out of 927 companies for Days Payable. This puts Teva Pharmaceutical Industries in the upper half of its industry. The industry median Days Payable is 90.38. Teva Pharmaceutical Industries' value of 118.92 is 31.6% above this benchmark. Historically, Teva Pharmaceutical Industries' own Days Payable has ranged from 68.63 to 107.74 over the past decade. While the company's 10-year median is 74.19 vs. the industry median of 90.38, Teva Pharmaceutical Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teva Pharmaceutical Industries's current Days Payable of 118.92 is 31.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Teva Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current Days Payable is 118.92, which is 60% above median its own 10-year median of 74.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (BSP:T1EV34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$52.47, compared to a current price of R$81.30 — trading 54.9% above its estimated fair value. The current Days Payable is 118.92, which is 60% above median its 10-year median of 74.19 and 31.6% above the Drug Manufacturers industry median of 90.38. Teva Pharmaceutical Industries' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Teva Pharmaceutical Industries (BSP:T1EV34), the current Days Payable is 118.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teva Pharmaceutical Industries (BSP:T1EV34) Overvalued in 2026?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued.
The current stock price of R$81.30 is trading 54.9% above its estimated GF Value™ of R$52.47.
GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.
Key valuation signals for BSP:T1EV34:
Days Payable: 118.92 (60% above median its 10-year median of 74.19)
GF Value™: R$52.47 vs. price of R$81.30 (54.9% above fair value)
Industry Position: 31.6% above the Drug Manufacturers median (#363 of 927)
No single metric tells the full story. See the BSP:T1EV34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teva Pharmaceutical Industries Business Description
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
10GF Score
Get the complete analysis for BSP:T1EV34
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:T1EV34 has been successfully added to your 
